DOSAGE OF CISPLATIN AND RELATED TOXICITY OF CANCER PATIENTS BASED ON BODY FAT AND MUSCLE MASS

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Scientific Journal, ESJ

• Publication date

  2015-02-26

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• ARCHIVES OF INTERNAL MEDICINE Hospital-Acquired Pressure Ulcers: Risk Factors and Use of Preventive Devices

  2017cited by this paper
• Determination of cisplatin in blood plasma by liquid chromatography with mass spectrometry detection

  2013cited by this paper
• Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis.

  2013cited by this paper
• Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

  2012cited by this paper
• Clinical Practice Guideline: Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline

  2012cited by this paper
• The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.

  2011cited by this paper
• Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer.

  2011cited by this paper
• Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma.

  2011cited by this paper
• Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines.

  2011influential reference
• Prevalence and trends in obesity among US adults, 1999-2008.

  2010cited by this paper
• The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

  2009cited by this paper
• Obesity and cancer treatment: weighing the evidence.

  2008cited by this paper
• Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.

  2008cited by this paper
• Establishing a standard definition for child overweight and obesity worldwide: international survey.

  2008cited by this paper
• Effect of obesity on survival in epithelial ovarian cancer

  2007cited by this paper
• Obesity and mortality in men with locally advanced prostate cancer

  2007cited by this paper
• Definitions and demographics of obesity: diagnosis and risk factors.

  2005cited by this paper
• Undertreatment of obese women receiving breast cancer chemotherapy.

  2005cited by this paper
• Body Mass Index in Relation to Ovarian Cancer Survival

  2005cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinoma

  2003cited by this paper
• Dietary carbohydrate's effects on lipogenesis and the relationship of lipogenesis to blood insulin and glucose concentrations

  2002cited by this paper
• Predictors of plasma triglyceride elevation in patients participating in a coronary atherosclerosis treatment program.

  2001cited by this paper
• Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns.

  2000cited by this paper
• Changes in plasma lipoproteins during low-fat, high-carbohydrate diets: effects of energy intake.

  2000cited by this paper
• The effect of body mass index and oestrogen receptor level on survival of breast cancer patients.

  1997cited by this paper
• Evaluation of long-term toxicity after chemotherapy for testicular cancer.

  1996cited by this paper
• Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

  1994cited by this paper
• Persistence of Hypertriglyceridemic Effect of Low-Fat High-Carbohydrate Diets in NIDDM Patients

  1989cited by this paper
• Commission on Biochemical Nomenclature

  1987cited by this paper
• Drugs five years later. Cisplatin.

  1984cited by this paper
• Body weight and prognosis in breast cancer

  1982cited by this paper
• Dose-response effect of adjuvant chemotherapy in breast cancer.

  1981cited by this paper
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

  1966cited by this paper

• No citing papers are available for this paper.